Literature DB >> 20004948

IMP3 expression is correlated with histologic grade of lung adenocarcinoma.

Jennifer J Findeis-Hosey1, Qi Yang, Betsy O Spaulding, Hanlin L Wang, Haodong Xu.   

Abstract

Insulin-like growth factor II mRNA binding protein 3 is an oncofetal protein that is expressed in multiple malignancies. This study aimed to determine the correlation of insulin-like growth factor II mRNA binding protein 3 expression with histologic grade of lung adenocarcinoma. Eighty-nine cases, including 11 atypical adenomatous hyperplasias, 10 pure bronchioloalveolar carcinomas, 36 well-differentiated adenocarcinomas and 41 moderately or poorly differentiated adenocarcinomas, were immunohistochemically studied using a monoclonal antibody against insulin-like growth factor II mRNA binding protein 3. Twenty-nine (70.7%) of 41 moderately to poorly differentiated adenocarcinomas were positive for insulin-like growth factor II mRNA binding protein 3, with 26 (89.7%) tumors demonstrating either a strong staining or staining in greater than 30% of tumor cells. Four (40.0%) of 10 bronchioloalveolar carcinomas and 13 (36.1%) of 36 well-differentiated adenocarcinomas exhibited insulin-like growth factor II mRNA binding protein 3 positivity with a variable degree and percentage of tumor cells staining. When bronchioloalveolar carcinomas were present in a pure form or as a component of adenocarcinomas, positive insulin-like growth factor II mRNA binding protein 3 staining was always patchy, with less than 20% of tumor cells stained. Overall, the frequency of positive insulin-like growth factor II mRNA binding protein 3 staining was lower in bronchioloalveolar carcinomas and well-differentiated adenocarcinomas compared to moderately/poorly differentiated adenocarcinomas (P < .01). No insulin-like growth factor II mRNA binding protein 3 signal was detected in any case of atypical adenomatous hyperplasia. These findings show that insulin-like growth factor II mRNA binding protein 3 is strongly and diffusely expressed in a large proportion of moderately/poorly differentiated lung adenocarcinomas, in particular in the solid component of mixed subtype adenocarcinomas, less frequently expressed in well-differentiated adenocarcinomas and bronchioloalveolar carcinomas, and negative in atypical adenomatous hyperplasias. The higher frequency of expression in moderately/poorly differentiated adenocarcinomas suggests that insulin-like growth factor II mRNA binding protein 3 expression may be associated with an aggressive biological behavior. Copyright 2010 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004948     DOI: 10.1016/j.humpath.2009.10.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  16 in total

1.  IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes.

Authors:  Alessandro Del Gobbo; Annamaria Morotti; Anna Eleonora Colombo; Valentina Vaira; Giulia Ercoli; Chiara Pesenti; Eleonora Bonaparte; Elena Guerini-Rocco; Andrea Di Cristofori; Marco Locatelli; Alessandro Palleschi; Stefano Ferrero
Journal:  Med Oncol       Date:  2017-12-01       Impact factor: 3.064

2.  Prognostic value of the IASLC/ATS/ERS classification and IMP3 expression in lung adenocarcinoma of Chinese cases.

Authors:  Xiangjie Sun; Ping Wei; Chen Shen; Yusi Yang; Yiqin Wang; Yuan Li; Xiang Du
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

3.  Combined detection of p16(INK4a) and IMP3 increase the concordance rate between cervical cytologic and histologic diagnosis.

Authors:  Qingzhu Wei; Bo Fu; Jianghuan Liu; Jiabao Xu; Tong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

4.  Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA.

Authors:  R Mizutani; N Imamachi; Y Suzuki; H Yoshida; N Tochigi; T Oonishi; Y Suzuki; N Akimitsu
Journal:  Oncogene       Date:  2015-11-02       Impact factor: 9.867

5.  IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.

Authors:  Jinhai Yan; Qingzhu Wei; Wenjing Jian; Bo Qiu; Jing Wen; Jianghuan Liu; Bo Fu; Xinhua Zhou; Tong Zhao
Journal:  Lung       Date:  2015-11-25       Impact factor: 2.584

6.  IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma.

Authors:  Shuai Hu; Xiaofeng Wu; Bo Zhou; Zhenchao Xu; Jianjie Qin; Hao Lu; Ling Lv; Yun Gao; Lei Deng; Jie Yin; Guoqiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-20       Impact factor: 4.553

7.  Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.

Authors:  Kristian Ikenberg; Florian R Fritzsche; Ursina Zuerrer-Haerdi; Irina Hofmann; Thomas Hermanns; Helge Seifert; Michael Müntener; Maurizio Provenzano; Tullio Sulser; Silvia Behnke; Josefine Gerhardt; Ashkan Mortezavi; Peter Wild; Ferdinand Hofstädter; Maximilian Burger; Holger Moch; Glen Kristiansen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

8.  IMP3 can predict aggressive behaviour of lung adenocarcinoma.

Authors:  Renata Beljan Perak; Merica Glavina Durdov; Vesna Capkun; Veljka Ivcevic; Antonia Pavlovic; Violeta Soljic; Mari Peric
Journal:  Diagn Pathol       Date:  2012-11-28       Impact factor: 2.644

9.  Enhanced IMP3 Expression Activates NF-кB Pathway and Promotes Renal Cell Carcinoma Progression.

Authors:  Xuelian Pei; Muhan Li; Jun Zhan; Yu Yu; Xiaofan Wei; Lizhao Guan; Hakan Aydin; Paul Elson; Ming Zhou; Huiying He; Hongquan Zhang
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

Review 10.  Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?

Authors:  Jessica L Bell; Kristin Wächter; Britta Mühleck; Nikolaos Pazaitis; Marcel Köhn; Marcell Lederer; Stefan Hüttelmaier
Journal:  Cell Mol Life Sci       Date:  2012-10-16       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.